サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654380

米国の医薬品市場規模・シェア・動向分析レポート：分子別、製品タイプ別、投与経路別、疾患別、年齢層別、流通チャネル別、セグメント予測、2025～2030年

U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
米国の医薬品市場規模・シェア・動向分析レポート：分子別、製品タイプ別、投与経路別、疾患別、年齢層別、流通チャネル別、セグメント予測、2025～2030年
出版日: 2025年01月28日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の医薬品市場規模・動向

米国の医薬品市場規模は2024年に6,343億2,000万米ドルと推定され、2025～2030年にかけてCAGR 5.72％で成長し、2030年には8,839億7,000万米ドルに達すると予測されています。

この成長は、慢性疾患の有病率の上昇、高齢者の増加、政府機関による医療支出の増加、医薬品の購入しやすさと入手しやすさを改善するための広範な努力に起因しています。

米国の製薬産業は、治療の進歩や製品パイプラインの充実により大きな成長を遂げています。標的治療、生物製剤、個別化医療の開発は治療モデルを再構築し、がん、自己免疫疾患、遺伝性疾患などの複雑な疾患に対してより効果的な解決策を提供しています。遺伝性網膜疾患やある種のがんに対する治療のように、遺伝子治療やRNAベースの治療がFDAの承認を得ており、産業の勢いに貢献しています。特定のがんに対するCAR-T細胞療法などの最先端薬剤の承認は、精密医療への市場の注目の高まりを例証するものであり、以前は治療不可能であった疾患に希望を与えるものです。特筆すべき進歩は、がん治療を再定義する免疫腫瘍学治療の継続的な進歩です。

米国の医薬品市場では、GLP-1受容体作動薬とGLP-1/GIPデュアルアゴニストの画期的な臨床成績が、肥満治療の新たな基準を打ち立てた。GLP-1受容体作動薬やGLP-1/GIPデュアルアゴニストは、前例のない臨床結果をもたらす画期的な治療として注目されています。セマグルチドやティルゼパチドなどのこれらの薬剤は、最大25％の体重減少を示し、7％程度の体重減少しか達成できなかった以前の薬剤クラスを大きく上回っています。この画期的な進歩は、患者と医療提供者の双方にとって肥満治療のパラダイムを再構築し、長らく管理が困難とされてきた疾患に対する実行可能な医療的解決策を提供しました。デジタルヘルスツールの進歩と相まって、これらの治療は、薬理学的治療と技術、行動コーチング、個別化介入を組み合わせた統合ケアモデルの一部となっています。この包括的なアプローチは、肥満に対処するだけでなく、患者全体の転帰を改善し、米国の公衆衛生の大きな課題を克服する確かな道筋を示しています。

米国の医薬品研究開発費は市場成長の極めて重要な促進要因であり、同セグメントは新治療法の発見と開発に継続的に投資しています。2023年には、米国の製薬企業は800億米ドル以上を研究開発に費やしており、この数字は毎年増え続けています。Johnson & Johnson、Merck、Eli Lillyなどの大手企業は、高齢化や慢性疾患の増加に対応する革新的な医薬品開発の重要性を認識し、企業収益のかなりの部分を研究開発に充てています。

このような高水準の投資は、がん、免疫、希少疾患など、さまざまなセグメントにおける画期的な治療法の発見に拍車をかけています。オックスFord・アカデミックの記事によると、2023年の米国の医薬品支出は13.6％増の7,225億米ドルに達しました。この増加は、利用率の6.5％増、新薬による4.2％増、価格の2.9％増によってもたらされました。2023年に最も売れた医薬品はセマグルチドで、アダリムマブ、アピキサバンがこれに続きました。さらに、2023年には、連邦政府以外の病院における医薬品支出は1.1％減の371億米ドルとなったが、クリニックにおける支出は15.0％増の1,357億米ドルとなりました。クリニックの伸びは利用率の増加によるもので、新製品や価格変更の影響は軽微でした。連邦政府以外の病院では、利用率の低下が支出の減少につながったが、新薬と価格の影響はわずかでした。2024年に期待されるいくつかの新薬、特に専門治療、内分泌治療、がん治療が引き続き支出を牽引すると考えられます。

革新的な最新医薬品の市場導入が進んでいることも、米国の医薬品市場の重要な促進要因です。患者や医療プロバイダーが新しい治療の有効性を認識するようになるにつれ、より良い治療成績と副作用の少ない最先端治療への需要が高まっています。特に、がん、自己免疫疾患などにおける生物製剤、遺伝子治療、免疫療法の普及は著しいです。例えば、免疫腫瘍学で使用されるようなモノクローナル抗体の急速な採用は、治療状況を一変させ、市場情勢をリードするキイトルーダやオプジーボは、前年比売上高で目覚ましい伸びを示しています。最近、2024年9月、APIイノベーションセンターは米国の製薬の独立性を強化することを目的とした戦略的資金として1,400万米ドルを受領しました。この資金は、米国内での重要な医薬品原薬（API）製造能力の開発を支援し、サプライチェーンの強靭性を高め、海外供給源への依存を軽減するものです。このイニシアチブは、国内生産を強化し、国家安全保障を向上させ、必要不可欠な医薬品への一貫したアクセスを確保する取り組みと一致します。

しかし、主要な医薬品の特許切れは、米国の医薬品産業の成長にとって大きな抑制要因となっています。特許が切れると、ジェネリック医薬品が市場に参入し、先発医薬品の売上が激減することがよくあります。例えば、2023年1月、年間売上高200億米ドルを超えるAbbVieの大ヒット医薬品ヒュミラ（アダリムマブ）の特許が切れ、バイオシミラーが競合するようになりました。ブランド医薬品からジェネリック医薬品へのシフトは、オリジネーター企業の市場シェアを低下させ、その収益源に大きな影響を与えます。市場力学全体もジェネリック医薬品による価格圧力に影響され、先発企業は価格を下げるか、新たな市場ニッチを見つけることを余儀なくされます。この変化は、エンブレルやハーセプチンのような主要製品の特許が切れ、より安価な代替品への道が開かれた生物製剤市場において特に顕著です。

目次

第1章 米国の医薬品市場：調査手法と範囲

第2章 米国の医薬品市場：エグゼクティブサマリー

  • 市場スナップショット
  • セグメントスナップショット
  • 競合情勢のスナップショット

第3章 米国の医薬品市場の変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 米国の医薬品市場：分子タイプ別、展望、推定・動向分析

  • 米国の医薬品市場：分子タイプの変動分析
  • 生物製剤とバイオシミラー（高分子）
  • 従来の医薬品（小分子）

第5章 米国の医薬品市場：製品別、推定・動向分析

  • 米国の医薬品市場：製品の変動分析
  • ブランド
  • ジェネリック

第6章 米国の医薬品市場：タイプ別、推定・動向分析

  • 米国の医薬品市場：タイプ変動分析
  • 処方箋
  • 店頭

第7章 米国の医薬品市場：疾病別、展望、推定・動向分析

  • 米国の医薬品市場：疾病の展望と変動分析
  • 心血管疾患
  • がん
  • 糖尿病
  • 感染症
  • 神経疾患
  • 呼吸器疾患
  • 自己免疫疾患
  • 精神疾患
  • 胃腸障害
  • 女性の健康疾患
  • 遺伝性疾患と稀少遺伝性疾患
  • 皮膚疾患
  • 肥満
  • 腎臓疾患
  • 肝臓の病気
  • 血液疾患
  • 目の状態
  • 不妊症
  • 内分泌障害
  • アレルギー
  • その他

第8章 米国の医薬品市場：投与経路別、推定・動向分析

  • 米国の医薬品市場：投与経路の変動分析
  • 経口
  • 局所
  • 非経口
  • 吸入
  • その他

第9章 米国の医薬品市場：年齢層別、推定・動向分析

  • 米国の医薬品市場：年齢層の変動分析
  • 幼児と青少年
  • 成人
  • 高齢者

第10章 米国の医薬品市場：流通チャネルグループ別、推定・動向分析

  • 米国の医薬品市場：流通チャネルグループ変動分析
  • 病院薬局
  • 小売薬局
  • その他

第11章 競合情勢

  • 企業分類
  • 戦略マッピング
    • 新製品発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 主要企業の市場シェア分析、2024年
  • 企業ヒートマップ分析
  • 企業プロファイル
    • F. HOFFMANN-LA ROCHE LTD
    • NOVARTIS AG
    • ABBVIE INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • MERCK &CO., INC.
    • PFIZER INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • GSK PLC.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Pharmaceutical Market, By Disease, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 9 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain-Based Sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 U.S. Pharmaceutical Market Segmentation
  • FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • FIG. 11 Penetration & Growth Prospect Mapping
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 U.S. Pharmaceutical Market: Product outlook and key takeaways
  • FIG. 15 U.S. Pharmaceutical Market: Product movement analysis & market share 2024 & 2030
  • FIG. 16 Branded U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 17 Generics U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 18 U.S. Pharmaceutical Market: Type outlook and key takeaways
  • FIG. 19 U.S. Pharmaceutical Market: Type movement analysis & market share 2024 & 2030
  • FIG. 20 Prescription U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 21 OTC U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 22 U.S. Pharmaceutical Market: Therapeutic category outlook and key takeaways
  • FIG. 23 U.S. Pharmaceutical Market: Therapeutic category movement analysis & market share 2024 & 2030
  • FIG. 24 Oncology U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 25 Anti-infectives U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 26 Cardiovascular diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 27 CNS disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 28 Metabolic disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 29 GI disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 30 Respiratory diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 31 Others U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 32 U.S. Pharmaceutical Market: Formulation outlook and key takeaways
  • FIG. 33 U.S. Pharmaceutical Market: Formulation movement analysis & market share 2024 & 2030
  • FIG. 34 Tablets U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 35 Capsules U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 36 Injectables U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 37 Sprays U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 38 Suspensions U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 39 Powders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 40 Others formulation U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 41 U.S. Pharmaceutical Market: Age group outlook and key takeaways
  • FIG. 42 U.S. Pharmaceutical Market: Age group movement analysis & market share 2024 & 2030
  • FIG. 43 Children & Adolescents U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 44 Adults U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 45 Geriatric U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-4-68040-210-9

U.S. Pharmaceutical Market Size & Trends:

The U.S. pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to grow at a CAGR of 5.72% from 2025 to 2030, to reach an estimated value of USD 883.97 billion by 2030. This growth can be attributed to the rising prevalence of chronic diseases, increasing geriatric population, growing healthcare expenditure by government organizations, and extensive efforts to improve the affordability & accessibility of pharmaceuticals.

The U.S. pharmaceutical industry has experienced significant growth due to advancements in therapeutics and a robust product pipeline. The development of targeted therapies, biologics, and personalized medicine has reshaped treatment model, offering more effective solutions for complex conditions such as cancer, autoimmune diseases, and genetic disorders. Gene therapies and RNA-based treatments, like those for inherited retinal diseases and certain types of cancers, have gained FDA approvals, contributing to the industry's momentum. The approval of cutting-edge drugs such as CAR-T cell therapies for certain cancers exemplifies the market's growing focus on precision medicine, offering hope for previously untreatable conditions. A notable advancement is the continued progression in immuno-oncology treatments, which are redefining cancer care.

In the U.S. market for pharmaceuticals, the transformative clinical outcomes of GLP-1 receptor agonists and GLP-1/GIP dual agonists, have set a new benchmark for obesity treatment. As they are emerged as transformative therapies, delivering unprecedented clinical results. These medications, such as semaglutide and tirzepatide, have demonstrated weight loss of up to 25%, significantly outperforming earlier drug classes, which achieved only about 7% weight reduction. This breakthrough has reshaped the obesity treatment paradigm for both patients and providers, offering a viable medical solution to a condition long viewed as difficult to manage. Coupled with advances in digital health tools, these therapies are part of integrated care models that combine pharmacological treatments with technology, behavioral coaching, and personalized interventions. This comprehensive approach not only addresses obesity but also improves overall patient outcomes, presenting a credible pathway to overcoming a major public health challenge in the U.S.

Pharmaceutical R&D spending in the U.S. has been a pivotal driver of market growth, with the sector continuously investing in the discovery and development of new therapies. In 2023, pharmaceutical companies in the U.S. spent over USD 80 billion on R&D, a figure that continues to rise annually. Major companies like Johnson & Johnson, Merck, and Eli Lilly have earmarked significant portions of their revenues to R&D, recognizing the importance of developing innovative drugs to meet the demands of an aging population and the increasing prevalence of chronic diseases.

This high level of investment fuels the discovery of breakthrough therapies across various segments, including oncology, immunology, and rare diseases. According to an article by oxford Academic, in 2023, U.S. pharmaceutical spending rose by 13.6% to reach USD 722.5 billion. This increase was driven by a 6.5% rise in utilization, a 4.2% boost from new drugs, and a 2.9% uptick in prices. The top-selling drug of 2023 was semaglutide, followed by adalimumab and apixaban. Furthermore, In 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion. Clinic growth was driven by higher utilization, with a minor impact from new products and price changes. In nonfederal hospitals, lower utilization led to reduced spending, while new drugs and prices had a modest influence. Several new drugs expected in 2024, especially in specialty, endocrine, and cancer treatments, will continue to drive spending.

The growing market adoption of innovative and modern medicines is another key driver of the U.S. pharmaceutical market. As patients and healthcare providers become more aware of the effectiveness of new treatments, there is an increasing demand for cutting-edge therapies that offer better outcomes and fewer side effects. The uptake of biologics, gene therapies, and immunotherapies in oncology, autoimmune diseases, and other areas has been particularly notable. For example, the rapid adoption of monoclonal antibodies, such as those used in immuno-oncology, has transformed the treatment landscape, with market leaders like Keytruda and Opdivo showing impressive year-on-year sales growth. Recently, in September 2024, the API Innovation Center received USD 14 million in strategic funding aimed at strengthening U.S. pharmaceutical independence. The funding will support the development of critical Active Pharmaceutical Ingredients (API) manufacturing capabilities within the U.S., enhancing resilience in the supply chain and reducing reliance on foreign sources. This initiative aligns with efforts to bolster domestic production, improve national security, and ensure consistent access to essential medicines.

However, Patent expiration of key pharmaceutical drugs has emerged as a significant restraint for the growth of the U.S. pharmaceutical industry. Once patents expire, generic versions of these drugs can enter the market, often leading to a sharp decline in sales for the original branded drugs. For instance, in January 2023, the patent for AbbVie's blockbuster drug Humira (adalimumab), which generated over USD 20 billion in annual sales, expired, allowing biosimilars to compete. The shift from branded to generic drugs reduces the market share of originator companies and significantly impacts their revenue streams. The overall market dynamics are also affected by the pricing pressure brought on by these generics, forcing branded companies to reduce prices or find new market niches. This change is particularly evident in the biologics market, where patents for key products like Enbrel and Herceptin have expired, opening the door for cheaper alternatives.

U.S. Pharmaceutical Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. pharmaceutical market report based on molecule, product, type, disease, route of administration, age group, and distribution channel:

  • Molecule Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Biologics & Biosimilars (Large Molecules)
    • Monoclonal Antibodies
    • Vaccines
    • Cell & Gene Therapy
    • Others
  • Conventional Drugs (Small Molecules)
  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Branded
  • Generic
  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Prescription
  • OTC
  • Disease Outlook (Revenue, USD Billion, 2018 - 2030)
  • Cardiovascular diseases
  • Cancer
  • Diabetes
  • Infectious diseases
  • Neurological disorders
  • Respiratory diseases
  • Autoimmune diseases
  • Mental health disorders
  • Gastrointestinal disorders
  • Women's Health Diseases
  • Genetic and Rare genetic diseases
  • Dermatological conditions
  • Obesity
  • Renal diseases
  • Liver conditions
  • Hematological disorders
  • Eye conditions
  • Infertility conditions
  • Endocrine disorders
  • Allergies
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
  • Oral
    • Tablet Capsule
    • Suspensions
    • Other
  • Topical
  • Parenteral
    • Intravenous
    • Intramuscular
  • Inhalations
  • Other
  • Age Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Children & Adolescents
  • Adults
  • Geriatric
  • Distribution Channel Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. U.S. Pharmaceutical Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Objectives
    • 1.3.1. Objective - 1
    • 1.3.2. Objective - 2
    • 1.3.3. Objective - 3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. U.S. Pharmaceutical Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing healthcare spending by the government
      • 3.2.1.2. Improving affordability driven by rising per capita income
      • 3.2.1.3. Increasing awareness about healthcare among the population
      • 3.2.1.4. Increasing access to innovative and modern medicines
      • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
      • 3.2.1.6. Rising chronic diseases and geriatric population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. COVID-19 pandemic
      • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
      • 3.2.2.3. Increasing price-sensitivity of customers for non-reimbursed drugs
      • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis

Chapter 4. U.S. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

  • 4.1. Molecule Type Outlook: Movement Analysis
  • 4.2. Biologics & Biosimilars (Large Molecules)
    • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.1.1 Biologics & Biosimilars (Large Molecules)
      • 4.2.1.2 Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.1.2.1 Monoclonal Antibodies
        • 4.2.1.2.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.3.1 Vaccines
      • 4.2.3.2 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.3.1.1 Cell & Gene Therapy
        • 4.2.3.3.2 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.5.1 Others
      • 4.2.5.2 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3. Conventional Drugs (Small Molecules)
    • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Market: Product Movement Analysis
  • 5.2. Branded
    • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Generic
    • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Market: Type Movement Analysis
  • 6.2. Prescription
    • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3. OTC
    • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Pharmaceutical Market: Disease Outlook Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Market: Disease Outlook Movement Analysis
  • 7.2. Cardiovascular diseases
    • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Cancer
    • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Diabetes
    • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Infectious diseases
    • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Neurological disorders
    • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Respiratory diseases
    • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. Autoimmune diseases
    • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.9. Mental health disorders
    • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.10. Gastrointestinal disorders
    • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.11. Women's Health Diseases
    • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.12. Genetic and Rare genetic diseases
    • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.13. Dermatological conditions
    • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.14. Obesity
    • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.15. Renal diseases
    • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.16. Liver conditions
    • 7.16.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.17. Hematological disorders
    • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.18. Eye conditions
    • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.19. Infertility conditions
    • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.20. Endocrine disorders
    • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.21. Allergies
    • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.22. Others
    • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. U.S. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Market: Route of Administration Movement Analysis
  • 8.2. Oral
    • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Topical
    • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 8.4.1.1. Intravenous
      • 8.4.1.2. Intramuscular
  • 8.5. Inhalations
    • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Other
    • 8.6.1. Other Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. U.S. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Market: Age Group Movement Analysis
  • 9.2. Children & Adolescents
    • 9.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3. Adults
    • 9.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4. Geriatric
    • 9.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. U.S. Pharmaceutical Market: Distribution Channel Group Estimates & Trend Analysis

  • 10.1. U.S. Pharmaceutical Market: Distribution Channel Group Movement Analysis
  • 10.2. Hospital Pharmacy
    • 10.2.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.3. Retail Pharmacy
    • 10.3.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.4. Others
    • 10.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
  • 11.2. Strategy Mapping
    • 11.2.1. NEW PRODUCT LAUNCH
    • 11.2.2. PARTNERSHIPS
    • 11.2.3. ACQUISITION
    • 11.2.4. COLLABORATION
    • 11.2.5. FUNDING
  • 11.3. Key Company Market Share Analysis, 2024
  • 11.4. Company Heat Map Analysis
  • 11.5. Company Profiles
    • 11.5.1. F. HOFFMANN-LA ROCHE LTD
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Product Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. NOVARTIS AG
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Product Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. ABBVIE INC.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Product Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. JOHNSON & JOHNSON SERVICES, INC.
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Product Benchmarking
      • 11.5.4.4 Strategic Initiatives
    • 11.5.5. MERCK & CO., INC.
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Product Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. PFIZER INC.
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Product Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. BRISTOL-MYERS SQUIBB COMPANY
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Product Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. SANOFI
      • 11.5.8.1. Company Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Product Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. GSK PLC.,
      • 11.5.9.1. Company Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Product Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 11.5.10.1. Company Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Product Benchmarking
      • 11.5.10.4. Strategic Initiatives